Suitability of Small Bronchoscopic Tumour Specimens for Lung Cancer Genotyping

Abstract

Background: Biomarker-driven clinical trials in advanced non-small cell lung cancer (NSCLC) usually accept biopsy specimens only, as cytology specimens are supposed to be more challenging due to low neoplastic cell content and suboptimal DNA quantity. Objectives: We aimed to evaluate 2 aspects of bronchoscopic biopsy and cytology specimens: (1) the proportion of neoplastic cells and quantity of DNA extracted, and (2) the detection limit of the Scorpion amplification refractory mutation system on endoscopic samples obtained in daily clinical practice. Methods: We screened 679 patients with advanced-stage NSCLC for the presence of an activating EGFR mutation according to the guidelines of the European Society of Medical Oncology. Their diagnostic tumour tissue samples were characterized. A dilution experiment was performed to determine the minimal proportion of neoplastic cells for a reliable test result. Results: Surgical biopsies, bronchoscopic forceps biopsy samples and needle aspiration cytology specimens exhibited a median tumour cell proportion of 70 versus 30 versus 20% and a DNA quantity of 2,500 versus 1,610 versus 1,440 ng, respectively. The overall EGFR mutation rate was 11%, with no differences between different sample types. Dilution experiments showed that the detection limit depends on the type of mutation. A neoplastic cell content of at least 10 and 25% for exon 19 deletions and exon 21 L858R point mutation, respectively, was required for a true negative result. Conclusions: Bronchoscopic forceps biopsy and needle aspiration cytology specimens are suitable for accurate EGFR mutation analysis using single-gene quantitative real-time polymerase chain reaction. Technologies with a better analytical sensitivity are evolving and should consider these endoscopic tumour specimens.

A Randomized Clinical Trial of Flex 19G Needles versus 22G Needles for Endobronchial Ultrasonography in Suspected Lung Cancer

“…In particular, predictive genetic alteration testing is relevant as the molecular complexity of lung cancer is evolving [10]. Targeted PCR-based sequencing can be performed on > 80% of the routine EBUS-TBNA specimens, but only a limited number of studies did evaluate next-generation sequencing (NGS) assays performed on fine needle aspirations [11][12][13][14].…”

Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations

“…Other concerns are related to the performance characteristics of the technology used for mutation analysis, e.g. the detection threshold, the mutation spectrum, the cost of the consumables and the hands-on time [ 25 ].…”

Endobronchial ultrasound in diagnosing and staging of lung cancer by Acquire 22G TBNB versus regular 22G TBNA needles: study protocol of a randomised clinical trial

“…With the advent of EBUS-TBNA and EUS-FNA, the ability to accurately assess the PD-L1 expression and molecular profiling on small, cytological tissue samples has become of great importance. Although the use of cell blocks and improved sequencing techniques have expanded the possibilities for PD-L1 assessment, 10–14 the success rate of PD-L1 expression and molecular profiling remains suboptimal at cytology compared with histology. 15–17 …”